ReviewMedical oncology (Northwood, London, England)2025
The trio of Candida albicans, immune cells, and cancer progression: a complex interplay driving tumorigenesis.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida albicans (C. albicans) has been identified as an opportunistic pathogen that resides as commensal in healthy population but transform into pathogen in immunocompromised individuals. Beyond secondary infection, current studies are evident it's complicated and concerning association in cancer progression. However, the interplay behind this association is still unknown. Here, we explored the trio association between the host's immune response, C. albicans and cancer progression. We acknowledged the gaps in existing knowledge, particularly the understudied mechanisms through which C. albicans promote oncogenesis and tumor progression. Key areas included chronic inflammation, influence on tumor microenvironment, immune modulation, and biofilm formation. Additionally, the review uncovered novel insights that could highlight the necessary future directions, specifically in development of therapeutics targeting this triad for better cancer management.
Indexed as
Identifiers
41125844What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.